Castle Biosciences Inc (CSTL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Castle Biosciences Inc stock (CSTL) is currently trading at $25.27. Castle Biosciences Inc PS ratio (Price-to-Sales) is 2.16. Analyst consensus price target for CSTL is $48.50. WallStSmart rates CSTL as Sell.
- CSTL PE ratio analysis and historical PE chart
- CSTL PS ratio (Price-to-Sales) history and trend
- CSTL intrinsic value — DCF, Graham Number, EPV models
- CSTL stock price prediction 2025 2026 2027 2028 2029 2030
- CSTL fair value vs current price
- CSTL insider transactions and insider buying
- Is CSTL undervalued or overvalued?
- Castle Biosciences Inc financial analysis — revenue, earnings, cash flow
- CSTL Piotroski F-Score and Altman Z-Score
- CSTL analyst price target and Smart Rating
Castle Biosciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Castle Biosciences Inc (CSTL) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Castle Biosciences Inc (CSTL) Key Strengths (2)
93.31% of shares held by major funds and institutions
Trading at 1.58x book value, attractively priced
Supporting Valuation Data
Castle Biosciences Inc (CSTL) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Earnings declining -51.60%, profits shrinking
Company is losing money with a negative profit margin
Revenue growing slowly at 0.80% annually
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.16x sales
Castle Biosciences Inc (CSTL) Detailed Analysis Report
Overall Assessment
This company scores 31/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 1.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Book. Valuation metrics including Price/Book (1.58) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, EPS Growth. Some valuation metrics including Price/Sales (2.16) suggest expensive pricing. Growth concerns include Revenue Growth at 0.80%, EPS Growth at -51.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -5.21%, Operating Margin at -4.40%, Profit Margin at -7.02%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -5.21% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 0.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CSTL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CSTL's Price-to-Sales ratio of 2.16x trades at a deep discount to its historical average of 12.05x (9th percentile). The current valuation is 95% below its historical high of 43.54x set in Dec 2019, and 54% above its historical low of 1.4x in May 2025. Over the past 12 months, the PS ratio has expanded from ~1.8x, reflecting growing market expectations outpacing revenue growth.
Compare CSTL with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Castle Biosciences Inc (CSTL) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Castle Biosciences Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 344M with 1% growth year-over-year. The company is currently unprofitable, posting a -7.0% profit margin.
Key Findings
Generating 20M in free cash flow and 27M in operating cash flow. Earnings are translating into actual cash generation.
Debt-to-equity ratio of 0.08 indicates a conservative balance sheet with 86M in cash.
The company is unprofitable with a -7.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Castle Biosciences Inc.
Bottom Line
Castle Biosciences Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Castle Biosciences Inc(CSTL)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Castle Biosciences Inc. is a pioneering company in the diagnostics sector, focused on transforming patient care through its innovative gene-expression profiling tests, particularly in skin cancer. Its leading product, DecisionDx®-Melanoma, plays a crucial role in the management of melanoma by providing vital insights into risk stratification and guiding treatment decisions based on gene expression analysis. Committed to advancing precision medicine, the company leverages its proprietary technology to develop additional assays that address significant clinical needs. With a strong emphasis on research and development and a promising pipeline, Castle Biosciences is well-positioned for sustainable growth while enhancing clinical outcomes and delivering value to shareholders in the dynamic oncology market.